COMPARISON BETWEEN OLANZAPINE AND HALOPERIDOL and Seeman40 also criticize the fact that clinical trials generally use high doses of typical antipsychotics i.e., 1020 mg day of haloperidol ; , which give rise to D2 occupancy of greater than 90%; this compares to doses of atypical antipsychotics that give rise to D2 receptor occupancy of less than 80%. In fact, clinical studies with haloperidol do not suggest any advantage for dosages exceeding 5 mg day.41 Low doses 15 mg day ; of haloperidol induce 60%80% dopamine D2 receptor occupancy, which seems to be adequate to produce a clinically efficient neuroleptic response.42 As for olanzapine, Kapur and his group31 argued that at clinical doses this neuroleptic occupies more than 60% of D2 receptors and, if used at doses above 20 mg day, occupies more than 80% of dopamine D2 receptors. They concluded that D2 receptor occupancy with olanzapine is greater than that of clozapine, and comparable to that of typical neuroleptics.31 This is consistent with our results. In our study, doses of haloperidol 5.6 mg day ; remain within the low therapeutic range, whereas olanzapine doses 13.8 mg day ; were slightly over the recommended range for that age group 1012mg day ; . This may explain why the haloperidol- and olanzapine-treated patients had equivalent striatal D2 receptor occupancy. Even if doses and binding considerations might explain the absence of difference between the two drugs D2 receptors occupancy, this does not explain why patients treated with olanzapine had no procedural learning disturbances, while those treated with haloperidol had noticeable deficits. Olanzapine may have some protective properties against its D2 affinity. One possibility is that the anticholinergic properties of olanzapine may modulate its own D2-blocking effect within the striatum.43 It is well known that substances with anticholinergic properties may have a protective effect against D2antagonist-induced striatal dysfunction. This constitutes the theoretical premise for administering anticholinergic substances to reduce neuroleptic-induced extrapyramidal symptoms in schizophrenia. On the other hand, patients treated with haloperidol in the present study received concurrent anticholinergic medication, and this has not prevented their procedural learning deficits. In addition, clinical scales of extrapyramidal symptoms were not different between the haloperidol- and olanzapine-treated patients, suggesting that the anticholinergic treatment in the haloperidol group was sufficient to compensate for the extrapyramidal symptoms but not the procedural learning disturbances. In other words, the procedural learning tests may be more sensitive than the extrapyramidal symptom scale at detecting neuroleptic-induced striatal dysfunction. Another explanation may be related to the relative 5HT2 D2 receptor affinity of the medications. Greater serotonin 5-HT2 than dopamine D2 activity is a characteristic shared by atypical neuroleptics.32, 44, 45, 46, Olanzapine is classified as an atypical neuroleptic and possesses greater in vitro 5-HT2 than D2 receptor affinity.32 Haloperidol is a highly selective dopaminergic D2 receptor antagonist, and is devoid of 5-HT2 receptor activities.48 Higher 5-HT2 than D2 receptor affinity of neuroleptics has been found to be associated with a reduced incidence of extrapyramidal symptoms, 21 presumably due to a compensating effect of the 5-HT2 blocking activity over the D2 blocking activity in the basal ganglia. Although the mechanism underlying this effect is not fully understood, it may involve a 5-HT2 blockade of the inhibiting serotoninergic terminals arising from the raphe and projecting to the dopaminergic terminals in the striatum.19, 31, 46, 49 This 5-HT2 receptor blockade would increase the dopaminergic firing, thereby compensating for the D2 receptor blockade. It has been suggested previously18 that, at therapeutic doses, atypical neuroleptics do not reach a critical receptor occupancy in the nigrostriatal system presumably associated with extrapyramidal symptoms and procedural learning deficits ; , while at these doses these substances may occupy significant 5-HT2 receptors in the mesolimbic and mesocortical systems presumably associated with schizophrenic symptoms ; . This would protect against striatal dysfunction when treating for psychotic symptoms. However, our finding of similar striatal binding of 123IIBZM in the haloperidol and olanzapine groups does not favor this hypothesis. It has also been suggested that the protective effect of olanzapine in the striatum is related to its high 5-HT1A receptor agonist activity.50 These somatodendritic serotonin autoreceptors have been found in high numbers in the raphe nuclei, where they modulate the firing of serotoninergic neurons. 5-HT1A agonists like olanzapine inhibit the firing of serotoninergic neurons, once again increasing the level of dopamine in the striatum, which would have a compensating effect on its D2 receptor occupancy. The absence of any such compensating effect in the haloperidol group would, in contrast, favor striatal dysfunctions and procedural learning disturbances. Finally, differences in procedural learning in our two groups of patients could also be explained by social and clinical factors that influence the choice of an antipsy.

COMPARISON BETWEEN OLANZAPINE AND HALOPERIDOL and Seeman40 also criticize the fact that clinical trials generally use high doses of typical antipsychotics i.e., 1020 mg day of haloperidol ; , which give rise to D2 occupancy of greater than 90%; this compares to doses of atypical antipsychotics that give rise to D2 receptor occupancy of less than 80%. In fact, clinical studies with haloperidol do not suggest any advantage for dosages exceeding 5 mg day.41 Low doses 15 mg day ; of haloperidol induce 60%80% dopamine D2 receptor occupancy, which seems to be adequaols Search this Thread , # 1 Vindiuz Regular Member Join Date: Jun 2005 forum.">

Soma Congenital Hypertrichosis Lanuginosa This is a rare, autosomal dominant condition characterized by the retention and continued synchronized growth of the fetal lanugo hair. One third of cases have been reported to be sporadic.16 The thick coat of lanugo hair may be present at birth or develop within the first few months of life. The hair is silvery-gray and may grow to as long as 5 cm. The glabrous areas of the body are spared: palms, soles, lips, glans penis, and terminal phalanges. The amount of hair may regress but the norm is for the condition to progress. At puberty, longer lanugo hairs grow in the secondary sexual sites rather than the usual terminal hair. There are usually no associated features. Congenital Syndromes With Hypertrichosis Hypertrichosis with gingival fibromatosis, hypertrichosis with osteochondrodysplasia, and X-linked hypertrichosis are rare forms of congenital hypertrichosis and can be distinguished from congenital hypertrichosis lanuginosa by the nonsynchronous growth of hair, the presence of the associated abnormalities, and the fact that the hair becomes pigmented at puberty. Cornelia de Lange syndrome is rare and consists of generalized hypertrichosis and abundant scalp hair with low frontal and nuchal hair lines. The eyebrows are bushy and meet in the center, and the eyelashes are long and curled. The syndrome may be associated with physical and or mental retardation, characteristic facies, short digits, a high arched palate, and a distinctive low-pitched cry. Rubinstein-Taybi syndrome is the combination of generalized hypertrichosis, physical. Has received , 500 from the Common Grounds Group U.S.A. to study "Stability of Liposomal DNA Vectors." Florida A&M. Folakemi Odedina has received 8, 902 from the U.S. Department of the Army for the study, "Development and Validation of a Model of Prostate Cancer Screening in AfricanAmerican Men." Adrienne Hollis has been granted , 820 by U.S. Department of Health and Human Services, Centers for Disease Control, for research titled, "Development of Toxicology Curriculum for Communities." University of Florida. Hartmut Derendorf has received funding from the Bayer Group in the amount of , 875 for one year for the project titled, "Determination of the Kill Curves of Faropenem Daloxate in Three Different Bacterial Strains." Guenther Hochhaus has received a grant of , 325 from Schwarz Pharm. AG for one year to study, "Stability Study in Fresh Human Plasma in Vitro-Schwarz Research Contract." Whei-Mei Wu has been awarded , 391 from Baker Norton Pharmaceuticals for one year for the project titled, "Distribution, Stability, Metabolism and Pharmacokinetic Studies of BNP-166." David Brushwood has received funding from the Institute for Advancement of Community Pharmacy in the amount of , 000 for one year for the project titled, "Unit-of-Use Packaging to Improve Quality in Pharmacy." Carole Kimberlin has received a NIH grant of 0, 000 for the project titled "Conquering Pain Enabling Dialogue Through CD-ROM Web." Michael Asmus has received , 000 from the American College of Clinical Pharmacy for two years for the project titled, "In-Vivo Comparison of Pulmonary Deposition from Jet Nebulizers." Janet Karlix has received funding from Novartis-United States in the amount of , 406 for one year for the project titled, "Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of FTY720 vs. Mycophenolate Mofetil MMF ; in Combination with Neoral and Corticosteroids in de novo Renal Transplant Recipients." Mercer University. Michael W. Jann has been awarded a 5, 000 grant from Pfizer for a double-blind placebo controlled trial of "Pregabalin for the Treatment of Chronic Pain Associated with Shingles." He has also received a contract of 2, 800 from Althea Development Corporation to investigate, "Enhanced in vitro Transdermal Delivery by Microcorporation and Other Active Energy Based Flux Enhancement." Ajay K. Banga, Mark E. Rothenberg and John M. Holbrook have received a two-year 8, 420 contract from Altea Development Corporation, Atlanta, GA, to study, "Delivery of Plasmid DNA and Protein Antigens through Microporated Skin." Midwestern University-Chicago. Tammi Garzanelli has been awarded a , 000 grant from the APhA Foundation to "Develop and Implement a Lipid Mangement Program at Cub Pharmacy in Wheaton Illinois." Janet Ritter has received a grant of , 250 from Merck Pharm. Co. for "Establishment of an Asthma Education Program in an Outpatient Clinic." University of Illinois at Chicago. Linda Bressler has received funding from Taiho Pharmaceutical Co. in the amount of , 500, for the project titled, "Joint USA Japan Study of Oral Uracil Ftorafur UFT ; Plus Leucovorin in Patients." Eric Dadey has received , 227 from Celsus Incorporated for, "Biodistribution of Radiolabelled Intimatan." Alan Lau has been granted 3, 886 by Wyeth-Ayerst Laboratories to study, "VPA- 985 for Liver Cirrhosis and Ascites." John M. Pezzuto has received funding from the following sources: California Table Grape Commission in the amount of , 000 for the project titled, "Evaluation of the Cancer Chemoprevention Potential of Standarized Grape Extract; " NIH, 0, 293, for "Screening Of Various Chemopreventive Agents in the MNU-Induced Rat Mammary Tumor Model, " and 0, 956, also from NIH, for the project titled, "Chemoprevention Screening Employing a Transgenic Mouse Model Which Yields Prostate Tumors in Male Mice and Breast Tumors in Female Mice." Djaja Soejarto has received a grant from the National Endowment for the Humanities in the amount of , 470, for the project, "Ancient Mesopotamian Medical Therapies." Djaja Soejarto co96. Alzheimer disease was the most common classification in both the estrogen plus progestin 20 [50.0%] ; and the placebo 12 [57.1%] ; groups P .79, TABLE 3 ; . Seventy-five participants had a stroke during follow-up 39 in the estrogen plus progestin group and 36 in the placebo group ; , but only 1 participant diagnosed with probable dementia who was in the estrogen plus progestin group ; had a stroke during the trial before her diagnosis. Two other participants diagnosed with probable dementia in the estrogen plus progestin group had a history of stroke. Cheap soma Drug Activity: Nephrotropic Mechanism of Action: None Given Compound Name: None Given Method: Synthesis-Biochemical Use: A method for reversibly transforming and subculturing renal tubule cells for reversion to a somatic phenotype is claimed, comprising: a ; providing a quantity of renal tubule cells; b ; reversibly transforming said kidney cells to cause the cells to proliferate in vitro; c ; serially culturing said reversibly transformed cells to maintain a supply of cells; and d ; inducing said cultured, reversibly transformed renal tubule cells to revert to the somatic phenotype thereof. Also claimed is a method for processing blood. Useful for performing the functions for a dysfunctional kidney. Advantage: The method allows for serial culture of renal cells while retaining their ability to remove waste functions and to perform metabolic functions. Biological Data: No suitable data given. Chemistry: The cells are reversibly transformed by a temperature sensitive simian virus. 6 pages Drawings. Turbohalers are less technique dependent than aerosols, however, there are a few important points to be aware of: When you load the turbohaler, the dose of medication falls into place by gravity. You should always hold the turbohaler upright when you are loading the dose. The Doctor-Patient Relationship Should Retain The Moral Agency Of Both The Physician And The Patient 2-11 RELIGION, CONSCIENCE, AND CONTROVERSIAL CLINICAL PRACTICES Should health professionals refuse to provide treatments to which they object on moral grounds? Recent controversies regarding physicians and pharmacists who refuse to prescribe or dispense emergency and other contraceptives have sparked a debate about moral objections in providing some types of health care. Most people believe that health professionals should not have to engage in medical practices about which they have moral qualms. On the other hand, most people also believe that patients should have access to legal treatments, even in situations in which their physicians are troubled about moral implications of those treatments. Is it ethical for physicians to describe their objections to the patient? Should physicians have the right to refuse to discuss, provide, or refer patients for legal medical interventions to which they have religious or moral objections? Historically, doctors and nurses have not been required to participate in abortions or suicide, even where those interventions are legally sanctioned. This study aimed at understanding how physicians think about their ethical rights and obligations when conflicts emerge in clinical practice. Conclusion: On moral grounds, many physicians refuse to provide some services which society considers legal, and do not consider themselves obligated to disclose information about, or to refer patients, for legal but morally controversial, medical procedures. ---------Read the entire abstract. The message of this article extends far beyond the limited circumstances described. It extends to and sonata. COMPARISON BETWEEN OLANZAPINE AND HALOPERIDOL and Seeman40 also criticize the fact that clinical trials generally use high doses of typical antipsychotics i.e., 1020 mg day of haloperidol ; , which give rise to D2 occupancy of greater than 90%; this compares to doses of atypical antipsychotics that give rise to D2 receptor occupancy of less than 80%. In fact, clinical studies with haloperidol do not suggest any advantage for dosages exceeding 5 mg day.41 Low doses 15 mg day ; of haloperidol induce 60%80% dopamine D2 receptor occupancy, which seems to be adequaols Search this Thread , # 1 Vindiuz Regular Member Join Date: Jun 2005 forum."> Soma Congenital Hypertrichosis Lanuginosa This is a rare, autosomal dominant condition characterized by the retention and continued synchronized growth of the fetal lanugo hair. One third of cases have been reported to be sporadic.16 The thick coat of lanugo hair may be present at birth or develop within the first few months of life. The hair is silvery-gray and may grow to as long as 5 cm. The glabrous areas of the body are spared: palms, soles, lips, glans penis, and terminal phalanges. The amount of hair may regress but the norm is for the condition to progress. At puberty, longer lanugo hairs grow in the secondary sexual sites rather than the usual terminal hair. There are usually no associated features. Congenital Syndromes With Hypertrichosis Hypertrichosis with gingival fibromatosis, hypertrichosis with osteochondrodysplasia, and X-linked hypertrichosis are rare forms of congenital hypertrichosis and can be distinguished from congenital hypertrichosis lanuginosa by the nonsynchronous growth of hair, the presence of the associated abnormalities, and the fact that the hair becomes pigmented at puberty. Cornelia de Lange syndrome is rare and consists of generalized hypertrichosis and abundant scalp hair with low frontal and nuchal hair lines. The eyebrows are bushy and meet in the center, and the eyelashes are long and curled. The syndrome may be associated with physical and or mental retardation, characteristic facies, short digits, a high arched palate, and a distinctive low-pitched cry. Rubinstein-Taybi syndrome is the combination of generalized hypertrichosis, physical. Has received , 500 from the Common Grounds Group U.S.A. to study "Stability of Liposomal DNA Vectors." Florida A&M. Folakemi Odedina has received 8, 902 from the U.S. Department of the Army for the study, "Development and Validation of a Model of Prostate Cancer Screening in AfricanAmerican Men." Adrienne Hollis has been granted , 820 by U.S. Department of Health and Human Services, Centers for Disease Control, for research titled, "Development of Toxicology Curriculum for Communities." University of Florida. Hartmut Derendorf has received funding from the Bayer Group in the amount of , 875 for one year for the project titled, "Determination of the Kill Curves of Faropenem Daloxate in Three Different Bacterial Strains." Guenther Hochhaus has received a grant of , 325 from Schwarz Pharm. AG for one year to study, "Stability Study in Fresh Human Plasma in Vitro-Schwarz Research Contract." Whei-Mei Wu has been awarded , 391 from Baker Norton Pharmaceuticals for one year for the project titled, "Distribution, Stability, Metabolism and Pharmacokinetic Studies of BNP-166." David Brushwood has received funding from the Institute for Advancement of Community Pharmacy in the amount of , 000 for one year for the project titled, "Unit-of-Use Packaging to Improve Quality in Pharmacy." Carole Kimberlin has received a NIH grant of 0, 000 for the project titled "Conquering Pain Enabling Dialogue Through CD-ROM Web." Michael Asmus has received , 000 from the American College of Clinical Pharmacy for two years for the project titled, "In-Vivo Comparison of Pulmonary Deposition from Jet Nebulizers." Janet Karlix has received funding from Novartis-United States in the amount of , 406 for one year for the project titled, "Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of FTY720 vs. Mycophenolate Mofetil MMF ; in Combination with Neoral and Corticosteroids in de novo Renal Transplant Recipients." Mercer University. Michael W. Jann has been awarded a 5, 000 grant from Pfizer for a double-blind placebo controlled trial of "Pregabalin for the Treatment of Chronic Pain Associated with Shingles." He has also received a contract of 2, 800 from Althea Development Corporation to investigate, "Enhanced in vitro Transdermal Delivery by Microcorporation and Other Active Energy Based Flux Enhancement." Ajay K. Banga, Mark E. Rothenberg and John M. Holbrook have received a two-year 8, 420 contract from Altea Development Corporation, Atlanta, GA, to study, "Delivery of Plasmid DNA and Protein Antigens through Microporated Skin." Midwestern University-Chicago. Tammi Garzanelli has been awarded a , 000 grant from the APhA Foundation to "Develop and Implement a Lipid Mangement Program at Cub Pharmacy in Wheaton Illinois." Janet Ritter has received a grant of , 250 from Merck Pharm. Co. for "Establishment of an Asthma Education Program in an Outpatient Clinic." University of Illinois at Chicago. Linda Bressler has received funding from Taiho Pharmaceutical Co. in the amount of , 500, for the project titled, "Joint USA Japan Study of Oral Uracil Ftorafur UFT ; Plus Leucovorin in Patients." Eric Dadey has received , 227 from Celsus Incorporated for, "Biodistribution of Radiolabelled Intimatan." Alan Lau has been granted 3, 886 by Wyeth-Ayerst Laboratories to study, "VPA- 985 for Liver Cirrhosis and Ascites." John M. Pezzuto has received funding from the following sources: California Table Grape Commission in the amount of , 000 for the project titled, "Evaluation of the Cancer Chemoprevention Potential of Standarized Grape Extract; " NIH, 0, 293, for "Screening Of Various Chemopreventive Agents in the MNU-Induced Rat Mammary Tumor Model, " and 0, 956, also from NIH, for the project titled, "Chemoprevention Screening Employing a Transgenic Mouse Model Which Yields Prostate Tumors in Male Mice and Breast Tumors in Female Mice." Djaja Soejarto has received a grant from the National Endowment for the Humanities in the amount of , 470, for the project, "Ancient Mesopotamian Medical Therapies." Djaja Soejarto co96. Alzheimer disease was the most common classification in both the estrogen plus progestin 20 [50.0%] ; and the placebo 12 [57.1%] ; groups P .79, TABLE 3 ; . Seventy-five participants had a stroke during follow-up 39 in the estrogen plus progestin group and 36 in the placebo group ; , but only 1 participant diagnosed with probable dementia who was in the estrogen plus progestin group ; had a stroke during the trial before her diagnosis. Two other participants diagnosed with probable dementia in the estrogen plus progestin group had a history of stroke. Cheap soma Drug Activity: Nephrotropic Mechanism of Action: None Given Compound Name: None Given Method: Synthesis-Biochemical Use: A method for reversibly transforming and subculturing renal tubule cells for reversion to a somatic phenotype is claimed, comprising: a ; providing a quantity of renal tubule cells; b ; reversibly transforming said kidney cells to cause the cells to proliferate in vitro; c ; serially culturing said reversibly transformed cells to maintain a supply of cells; and d ; inducing said cultured, reversibly transformed renal tubule cells to revert to the somatic phenotype thereof. Also claimed is a method for processing blood. Useful for performing the functions for a dysfunctional kidney. Advantage: The method allows for serial culture of renal cells while retaining their ability to remove waste functions and to perform metabolic functions. Biological Data: No suitable data given. Chemistry: The cells are reversibly transformed by a temperature sensitive simian virus. 6 pages Drawings. Turbohalers are less technique dependent than aerosols, however, there are a few important points to be aware of: When you load the turbohaler, the dose of medication falls into place by gravity. You should always hold the turbohaler upright when you are loading the dose. The Doctor-Patient Relationship Should Retain The Moral Agency Of Both The Physician And The Patient 2-11 RELIGION, CONSCIENCE, AND CONTROVERSIAL CLINICAL PRACTICES Should health professionals refuse to provide treatments to which they object on moral grounds? Recent controversies regarding physicians and pharmacists who refuse to prescribe or dispense emergency and other contraceptives have sparked a debate about moral objections in providing some types of health care. Most people believe that health professionals should not have to engage in medical practices about which they have moral qualms. On the other hand, most people also believe that patients should have access to legal treatments, even in situations in which their physicians are troubled about moral implications of those treatments. Is it ethical for physicians to describe their objections to the patient? Should physicians have the right to refuse to discuss, provide, or refer patients for legal medical interventions to which they have religious or moral objections? Historically, doctors and nurses have not been required to participate in abortions or suicide, even where those interventions are legally sanctioned. This study aimed at understanding how physicians think about their ethical rights and obligations when conflicts emerge in clinical practice. Conclusion: On moral grounds, many physicians refuse to provide some services which society considers legal, and do not consider themselves obligated to disclose information about, or to refer patients, for legal but morally controversial, medical procedures. ---------Read the entire abstract. The message of this article extends far beyond the limited circumstances described. It extends to and sonata. COMPARISON BETWEEN OLANZAPINE AND HALOPERIDOL and Seeman40 also criticize the fact that clinical trials generally use high doses of typical antipsychotics i.e., 1020 mg day of haloperidol ; , which give rise to D2 occupancy of greater than 90%; this compares to doses of atypical antipsychotics that give rise to D2 receptor occupancy of less than 80%. In fact, clinical studies with haloperidol do not suggest any advantage for dosages exceeding 5 mg day.41 Low doses FREE HOSTING - hosted by 678Host.com - Get your FREE account now ! Need A Website? Get One Now